Christine Heironimus hired as New Director of Business Development and Strategic Network Acceleration
[RALEIGH, NC] — Wake Research is pleased to welcome Director of Business Development and Strategic Network Acceleration, Christine Heironimus. Heironimus has been in the research industry since 2003 and held positions as a site director, director of business development and director of sites development.
She has worked with Florida-based Meridien Research since 2005, as director of business development and later as executive director of site development with Insearch, the Meridien Research-owned subsidiary company providing business development leads to community-based clinical research investigators. Christine was instrumental in contributing to the growth of Insearch. At the time of her departure from the company in October of 2017, Insearch had 65 client sites and 200 Investigators who were relying on Insearch for study leads.
Heironimus has a degree in Business Administration from Wake Forest University.
About Wake Research
Wake Research is an organization of integrated investigational sites, committed to excellence, working closely with and meeting the needs of the biopharmaceutical, biotechnology, medical device and pharmaceutical industries. Wake Research‘s 13 sites are fully equipped to meet the needs of sponsors and CROs in the conduct of Phase I-IV clinical trials in a large variety of indications.
Wake Research is known for effectively combining strategic volunteer recruitment and retention with high-quality clinical trial conduct, using standardized operating procedures and centralized marketing and advertising to ensure rapid subject enrollment. Wake Research has conducted over 6,000 research studies for hundreds of pharmaceutical and biotech sponsors and CROs since 1984. Wake Research’s mission is to bring novel medications, biologics and devices through clinical research to as many people as possible while providing unparalleled service and exceptional value to clinical trial partners and stakeholders.